	Application No.	Applicant(s)
	09/424,951	SRIKANTHA ET AL.
Notice of Allowability	Examiner	Art Unit
	Desid A. Lee Lee	1000
	David A. Lambertson	1636
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. X This communication is responsive to the amendment filed Septmeber 22, 2003.		
2. The allowed claim(s) is/are 1,2,4-12,14-16 and 20.		
3. The drawings filed on <u>25 September 2003</u> are accepted by the Examiner.		
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some* c) ☐ None of the:		
1. Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No		
3. 🔲 Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
5. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.		
(a) ☐ The translation of the foreign language provisional application has been received.		
6. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE		
7. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
8. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) ☐ hereto or 2) ☐ to Paper No		
(b) including changes required by the proposed drawing correction filed, which has been approved by the Examiner.		
(c) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the margin according to 37 CFR 1.121(d).		
9. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)		
1☐ Notice of References Cited (PTO-892)	5☐ Notice of Informal Pat	ent Application (PTO-152)
2 Notice of Draftperson's Patent Drawing Review (PTO-948)		PTO-413), Paper No. <u>1103</u> .
3 Information Disclosure Statements (PTO-1449 or PTO/SB/08) Paper No	, 7⊠ Examiner's Amendme	ent/Comment
4 Examiner's Comment Regarding Requirement for Deposit	8☐ Examiner's Statement	t of Reasons for Allowance
of Biological Material	9 Other	
		•
		•



Application/Control Number: 09/424,951

Art Unit: 1636

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Teresa Spehar on November 25, 2003.

The application has been amended as follows:

In the specification:

On page 3, line 7, please replace "Figure 1" with "Figure 1A-B" in order to properly describe the panels contained in the indicated Figure.

On page 3, line 13, please replace "Figure 2" with "Figure 2A-E" in order to properly describe the panels contained in the indicated Figure.

On page 16, line 30, please replace "λSA115.1" with "λSA15.1" to correct a typographical error.

In the Claims:

1. An isolated polynucleotide that encodes a protein linked to phenotypic switching in *Candida albicans* that exhibits [70%] 90% or greater overall sequence identity to SEQ ID NO: 3 wherein said protein displays kinase activity.

Page 3

Application/Control Number: 09/424,951

Art Unit: 1636

9. The method according to claim 5, wherein step (B) comprises [effecting] performing a twodimensional gel electrophoresis.

10. The method according to claim 6, wherein step (B) comprises [effecting] performing a Northern Blot, a primer extension, or a ribonuclease protection assay.

20. A culture of bacterial strain containing the lambda phage [λSG15.1] λSA15.1 (Ca lambda 15.1).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David A. Lambertson whose telephone number is (703) 308-8365. The examiner can normally be reached on 6:30am to 4pm, Mon.-Fri., first Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucel, Ph.D. can be reached on (703) 305-1998. The fax phone number for the organization where this application or proceeding is assigned is (703) 305-3014.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

David A. Lambertson AU1636